Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RARE shares.
View RARE analyst ratings or view top-rated stocks.

10 brokers have issued 12 month price targets for Ultragenyx Pharmaceutical's shares. Their RARE share price targets range from $48.00 to $133.00. On average, they expect the company's stock price to reach $91.55 in the next year. This suggests a possible upside of 116.1% from the stock's current price.
View analysts price targets for RARE or view top-rated stocks among Wall Street analysts.

Ultragenyx Pharmaceutical's stock was trading at $47.82 on January 1st, 2024. Since then, RARE stock has decreased by 11.4% and is now trading at $42.36.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our RARE earnings forecast.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.65) by $0.13. The biopharmaceutical company earned $127.39 million during the quarter, compared to analyst estimates of $119.38 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 369.54% and a negative net margin of 139.70%. The business's revenue for the quarter was up 23.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.16) EPS.

ETFs with the largest weight of Ultragenyx Pharmaceutical (NASDAQ:RARE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), First Trust NYSE Arca Biotechnology Index Fund (FBT), Motley Fool Mid-Cap Growth ETF (TMFM), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA) and Simplify Health Care ETF (PINK).

Ultragenyx Pharmaceutical issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $500.0 million-$530.0 million, compared to the consensus revenue estimate of $504.3 million.

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

Ultragenyx Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Woodstock Corp (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Camille L Bedrosian, Corazon (Corsee) D Sanders, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Theodore Alan Huizenga and Thomas Richard Kassberg.
View institutional ownership trends.

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.